LCZ696, an Angiotensin Receptor-Neprilysin Inhibitor, Improves Cardiac Hypertrophy and Fibrosis and Cardiac Lymphatic Remodeling in Transverse Aortic Constriction Model Mice

Table 2

Characteristics of echocardiography in experimental mice.

	Sham	TAC	TAC + LCZ696 (60 mg/kg/d)
LVIDS (mm)	2.73 ± 0.17	3.80 ± 0.61	3.07 ± 0.25
LVIDD (mm)	3.98 ± 0.23	4.69 ± 0.45	4.02 ± 0.22
LVPWS (mm)	1.20 ± 0.06	1.35 ± 0.15	1.19 ± 0.12
LVPWD (mm)	0.72 ± 0.03	1.02 ± 0.13	0.89 ± 0.05
IVSS (mm)	1.12 ± 0.07	1.41 ± 0.15	1.21 ± 0.08
IVSD (mm)	0.69 ± 0.02	1.03 ± 0.12	0.88 ± 0.05
EF (%)	59.74 ± 1.78	38.17 ± 8.22	48.27 ± 4.35
FS (%)	31.33 ± 1.21	18.53 ± 4.31	24.01 ± 2.55
LV mass corrected (mg)	79.30 ± 8.02	173.47 ± 45.72	109.65 ± 8.28

Notes. LVIDS, left ventricular internal dimension in systole; LVIDD, left ventricular internal dimension in diastole; LVPWS, left ventricular systolic posterior wall thickness; LVPWD, left ventricular diastolic posterior wall thickness; IVSS, interventricular septal end-systolic thickness; IVSD, interventricular septal end-diastolic thickness; EF, left ventricular ejection fraction; FS, short-axis fraction; LV mass corrected, corrected left ventricular mass index. Data shown were obtained from eight mice in each group. Data are shown as the mean ± SD. versus the sham group; versus the TAC group.